Combination products hold tremendous promise for enhancing patient care, and as innovation in this space continues to progress, the U.S. Food and Drug Administration (FDA) expects to see a growing number of combination product submissions. However, because combination products are comprised of components (e.g., drugs, devices, and biologics) that are typically managed by different FDA centers, the review, approval, and post-market requirements related to these products can present a host of challenges for sponsors. Epstein Becker Green is adept at recognizing these challenges and helping clients navigate the complex regulatory, policy, and review management issues that can arise.
We have represented dozens of companies in their development of combination products. Also, given the complex regulatory environment, Epstein Becker Green created, launched, and continues to lead the Combination Products Coalition, a group of leading drug, biological product, and medical device manufacturers whose mission is focused on working collaboratively with FDA to improve the regulatory environment for combination products.
By partnering with Epstein Becker Green, clients benefit from our robust network of regulatory affairs contacts, quality consultants, reimbursement experts, compliance professionals, policy analysts, strategists, and other professionals who specialize in providing coordinated guidance and solutions across various segments of the health care industry.